Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Capsaicin

Copy Product Info
🥰Excellent
Catalog No. T1062Cas No. 404-86-4
Alias Zostrix, Qutenza, 8-Methyl-N-vanillyl-trans-6-nonenamide, (E)-Capsaicin

Capsaicin is an active natural component found in chili peppers and acts as a TRPV1 agonist (EC50 = 0.29 μM). It possesses multiple activities, including pain relief, antitumor, anti-inflammatory, antioxidant, and neuroprotective effects, as well as some neurotoxicity. Capsaicin can be used to establish itch models.

Capsaicin

Capsaicin

Copy Product Info
🥰Excellent
Purity: 99.88%
Catalog No. T1062Alias Zostrix, Qutenza, 8-Methyl-N-vanillyl-trans-6-nonenamide, (E)-CapsaicinCas No. 404-86-4
Capsaicin is an active natural component found in chili peppers and acts as a TRPV1 agonist (EC50 = 0.29 μM). It possesses multiple activities, including pain relief, antitumor, anti-inflammatory, antioxidant, and neuroprotective effects, as well as some neurotoxicity. Capsaicin can be used to establish itch models.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
50 mg$50In StockIn Stock
100 mg$75In StockIn Stock
1 mL x 10 mM (in DMSO)$54In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.88%
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Capsaicin is an active natural component found in chili peppers and acts as a TRPV1 agonist (EC50 = 0.29 μM). It possesses multiple activities, including pain relief, antitumor, anti-inflammatory, antioxidant, and neuroprotective effects, as well as some neurotoxicity. Capsaicin can be used to establish itch models.
Targets&IC50
HCT116 cells:40.16 μM, SK-MEL-2 cells:> 100 μM, K562 cells:49.41 μM, T47D cells:100 μM, MDA-MB-231 cells:120 μM, TRPV1 (HEK293 cells):0.29 μM (EC50), MCF-7 cells:49.97 μM, HeLa cells:> 50 μM, SKOV3 cells:22.03 μM, HEK293 cells:0.008 μM, BGC-823 cells:4.659 μM, A2058 cells:> 100 μM, FaDu cells:150 µM, B16 F10 cells:> 100 μM, NCI-H4 cells:30.66 μM
In vitro
METHODS: Human pharyngeal squamous carcinoma cells FaDu were treated with Capsaicin (50-300 µM) for 24-72 h. Cell viability was assayed using MTT Assay.
RESULTS: As the dose of Capsaicin increased, a decrease in enhanced cell growth was shown. Percentage of viable cells decreased with increase in incubation time. The IC50 value was about 150 µM. [1]
METHODS: Human oral epidermoid carcinoma cells KB were treated with Capsaicin (150-250 µM) for 24-48 h. Apoptosis was detected using Hoechst staining.
RESULTS: Capsaicin induced apoptosis in KB cells. [2]
In vivo
METHODS: To investigate the effects on thermoregulation and locomotor activity, Capsaicin (10-20 mg/kg, saline+3% ethanol+10% Tween 80) was administered by single gavage to C57BL/6J mice with WT and TRPV1 KO.
RESULTS: Oral administration of capsaicin resulted in a long-term increase in TRPV1-dependent acute hypothermia and TRPV1-independent locomotor activity, in addition to activation of brain circuits controlling thermoregulation and metabolism. [3]
METHODS: To assay neuroprotective activity, Capsaicin (5-20 mg/kg) was administered orally to mice given scopolamine once daily for seven days.
RESULTS: Capsaicin exerted empirical neuroprotective effects through restoration of mitochondrial function, antioxidant effects and modulation of pro-inflammatory cytokines. A 10 mg/kg dose of Capsaicin for seven consecutive days was the most effective dose. [4]
Disease Modeling Protocol
Trigeminal Neuropathic Pain Analgesia Model
  • Modeling Mechanism:

    Capsaicin, as a TRPV1-specific agonist, induces Ca²⁺ influx upon activation. This influx occurs through both the Ca²⁺/calpain pathway and the axonal microtubule depolymerization (increasing the content of free tubulin), jointly mediating TRPV1⁺ nociceptive nerve ending ablation. Nerve ending ablation reduces the transmission of abnormal pain signals, thereby alleviating mechanohypnosis. Moreover, this process is independent of TRPV1 S801 site phosphorylation.

  • Related Products:

    Capsaicin (T1062)

  • Modeling Method:

    Experimental Subject:

    Mice: C57BL/6J, TRPV1^Cre transgenic mice, ROSA^mT/mG transgenic mice, homozygous Calca^Cre mice, TRPV1 S801A knock-in mice, littermate wild-type (WT) mice (as controls); adult (22–30 g)

    Dosage and Administration Route:

    Pain model establishment: ION-CCI surgery (bilateral suborbital nerves ligated with 4.0 chromium sutures, 2 ligatures spaced 2 mm apart), resulting in stable mechanical hyperalgesia 14 days post-surgery;
    Capsaicin administration: 10 μg/20 μL capsaicin (dissolved in 25% PEG300+75% water) administered via subcutaneous injection into facial skin

    Dosing Frequency and Duration Model:

    Single injection of capsaicin 14 days post-ION-CCI surgery

  • Validation:

    Behavioral studies: 3-7 days after capsaicin injection, the mechanical pain threshold in the face of ION-CCI mice was significantly increased, and mechanical hyperalgesia was relieved; Molecular markers: Increased content of free tubulin in DRG neurons; Histology: Decreased density of TRPV1⁺ nerve endings and CGRP⁺ peptidergic nerve endings in facial and hind paw skin (ablation effect); Functional validation: Calcium imaging showed that capsaicin could induce Ca²⁺ influx in DRG neurons.

*Precautions: To facilitate the testing, a blind method was used. Mice were acclimatized for 20 minutes daily for 3 days prior to the experiment to reduce stress interference. After the experiment, mice were sacrificed, and DRG and facial/hind paw skin tissue were collected for immunohistochemistry, Western blot, or free microtubule detection.

*References:Arora V,et,al. Capsaicin-induced depolymerization of axonal microtubules mediates analgesia for trigeminal neuropathic pain. Pain. 2022 Aug 1;163(8):1479-1488.

Dry skin itching model
  • Modeling Mechanism:

    Capsaicin's target TRPV1 channel is upregulated under acetone-ether-water (AEW) induction due to skin barrier disruption: TRPV1⁺ sensory neurons proliferate in the trigeminal ganglion (TG), and the density of TRPV1⁺ sensory fibers innervating the skin increases; after enhanced TRPV1 sensitivity, capsaicin no longer induces pain-related rubbing behavior, but instead triggers itch-related scratching behavior. The core mechanism is the activation of the peripheral TRPV1 pathway and sensitization of the central itch signaling pathway.

  • Related Products:

    Capsaicin (T1062)

  • Modeling Method:

    Experimental Subject:

    Mice: C57BL/6 (expressing Pirt-GCaMP3 and TRPV1-PLAP transgenes) • Male • 8–10 weeks old

    Dosage and Administration Route:

    First shave the facial hair of the mouse, then perform AEW treatment (apply acetone-di-ethyl ether 1:1 mixture for 20 seconds, followed by distilled water for 30 seconds); after modelling, administer a subcutaneous injection of 500 nM capsaicin

    Dosing Frequency and Duration Model:

    AEW twice daily for 4–8 consecutive days; Capsaicin administered as a single subcutaneous injection

  • Validation:

    Capsaicin-induced AEW treatment mice showed significant scratching behavior (54.00±4.86 times), a substantial increase compared to the control group (5.25±1.44 times), while pain-related wiping behavior showed no significant change. Molecular markers: TRPV1 mRNA and protein expression were upregulated in TG, and the proportion of TRPV1⁺ neurons in the V3 branch increased (20.2% in the control group vs. 30.2% on day 4 of AEW). Histologically: The density of TRPV1⁺ sensory fiber innervation in the skin increased by 35.89%. Functional validation: Calcium imaging showed that the response rate of Capsaicin (50 nM, 500 nM, 1-10 μM) to TG neurons was significantly higher than that in the control group.

*Precautions: Behavioral tests were conducted 4-8 days after modeling (observing scratching/wiping behavior for 30-60 minutes). Mice were euthanized after the tests to collect TG and skin tissue. The experimental environment was maintained at 20-24℃ and 45%-65% humidity. Behavioral assessments were performed by blinded observers.

*References:Yu G,et,al. Enhanced itch elicited by capsaicin in a chronic itch model. Mol Pain. 2016 Apr 26;12:1744806916645349.

Cell Research
Capsaicin is dissolved in DMSO and stored, and then diluted with appropriate medium before use[3]. FaDu cells are plated at a density of 1×105 cells/well on 24-well plate. After overnight growth, the cells are treated with various concentrations of Capsaicin (0 μM, 50 μM, 100 μM, 150 μM, 200 μM, 250 μM, 300 μM, and 350 μM) for 24, 48 and 72 hours, with medium replacement every 24 hours. At the end of treatment, 30 μL of the tetrazolium compound MTT, and 270 μL of fresh medium are added. After further incubation for 4 hours at 37°C, 200 μL of 0.1 N HCl in 10% SDS is added into each well to dissolve the tetrazolium crystals. Finally, the absorbance at a wavelength of 540 nm is recorded using an ELISA plate reader[3].
SynonymsZostrix, Qutenza, 8-Methyl-N-vanillyl-trans-6-nonenamide, (E)-Capsaicin
Chemical Properties
Molecular Weight305.41
FormulaC18H27NO3
Cas No.404-86-4
SmilesC(NC(CCCC/C=C/C(C)C)=O)C1=CC(OC)=C(O)C=C1
Relative Density.1.1037 g/cm3 (Estimated)
Storage & Solubility Information
Storagekeep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 260 mg/mL (851.31 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+90% Saline: 1.53 mg/mL (5.01 mM), Solution.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM3.2743 mL16.3714 mL32.7429 mL163.7144 mL
5 mM0.6549 mL3.2743 mL6.5486 mL32.7429 mL
10 mM0.3274 mL1.6371 mL3.2743 mL16.3714 mL
20 mM0.1637 mL0.8186 mL1.6371 mL8.1857 mL
50 mM0.0655 mL0.3274 mL0.6549 mL3.2743 mL
100 mM0.0327 mL0.1637 mL0.3274 mL1.6371 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Capsaicin | purchase Capsaicin | Capsaicin cost | order Capsaicin | Capsaicin chemical structure | Capsaicin in vivo | Capsaicin in vitro | Capsaicin formula | Capsaicin molecular weight